tiprankstipranks
Trending News
More News >
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
Advertisement

Sonoma Pharmaceuticals (SNOA) AI Stock Analysis

Compare
340 Followers

Top Page

SNOA

Sonoma Pharmaceuticals

(NASDAQ:SNOA)

Rating:51Neutral
Price Target:
$5.50
▲(23.60% Upside)
Sonoma Pharmaceuticals' stock score is primarily influenced by strong technical indicators, with the stock trading above key moving averages. However, financial performance concerns, including profitability and cash flow challenges, and a negative P/E ratio weigh heavily on the score. The absence of earnings call data and corporate events means these factors did not influence the score.

Sonoma Pharmaceuticals (SNOA) vs. SPDR S&P 500 ETF (SPY)

Sonoma Pharmaceuticals Business Overview & Revenue Model

Company DescriptionSonoma Pharmaceuticals (SNOA) is a biopharmaceutical company focused on developing and commercializing innovative therapies for dermatology and other medical applications. The company specializes in the development of topical prescription and over-the-counter products that leverage its proprietary formulations, primarily centered around the use of stabilized hypochlorous acid. Sonoma's core products are aimed at treating various skin conditions, including acne, eczema, and wound care, catering to both healthcare professionals and consumers.
How the Company Makes MoneySonoma Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications and over-the-counter solutions. The company has established distribution agreements with various partners to enhance market reach and drive sales. Additionally, Sonoma may generate income through licensing agreements for its proprietary technologies and formulations, collaborating with other companies to expand its product offerings. The revenue model is supported by ongoing research and development efforts to introduce new products and improve existing ones, which can lead to increased market penetration and sales growth.

Sonoma Pharmaceuticals Financial Statement Overview

Summary
Sonoma Pharmaceuticals is facing significant financial challenges with declining revenues and persistent unprofitability. Although there is some balance sheet stability with reduced debt, the equity position is weakening. Negative cash flows indicate poor cash management.
Income Statement
45
Neutral
Sonoma Pharmaceuticals has faced consistent revenue challenges, with a notable decline in revenue over the years. The revenue growth rate is negative, indicating a shrinking top line. The company also struggles with profitability, as evidenced by negative profit margins across gross, net, and EBIT. Despite some improvements in gross profit margin, the overall performance remains weak.
Balance Sheet
50
Neutral
The balance sheet indicates a moderate financial position with challenges. The debt-to-equity ratio has improved due to reduced debt, yet the stockholders' equity has also decreased, reflecting a weakening financial foundation. The equity ratio is moderate, suggesting a balanced asset structure, but not particularly strong.
Cash Flow
40
Negative
Cash flow performance is concerning, with consistently negative operating and free cash flows. The company has managed financing inflows, yet the free cash flow growth has been negative, pointing to ongoing operational cash challenges. The cash flow to net income ratios reflect struggles in converting revenue into cash.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue14.91M14.29M12.73M13.27M12.63M18.63M
Gross Profit5.62M5.46M4.75M4.48M3.99M6.56M
EBITDA-3.53M-3.57M-4.53M-4.45M-5.70M-3.22M
Net Income-3.56M-3.46M-4.83M-5.15M-5.09M-3.95M
Balance Sheet
Total Assets14.59M13.69M14.74M16.23M18.84M14.99M
Cash, Cash Equivalents and Short-Term Investments3.60M5.37M3.13M3.82M7.40M4.22M
Total Debt675.00K305.00K608.00K849.00K1.37M2.67M
Total Liabilities10.54M9.28M8.60M8.25M10.15M9.62M
Stockholders Equity4.06M4.41M6.14M7.98M8.70M5.36M
Cash Flow
Free Cash Flow-1.37M-168.00K-2.42M-6.42M-4.38M-3.56M
Operating Cash Flow-1.19M-88.00K-2.40M-6.15M-4.25M-3.38M
Investing Cash Flow-181.00K-80.00K-2.00K-258.00K-99.00K388.00K
Financing Cash Flow2.34M3.03M1.68M2.49M7.40M3.31M

Sonoma Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.45
Price Trends
50DMA
3.67
Positive
100DMA
3.41
Positive
200DMA
3.04
Positive
Market Momentum
MACD
0.35
Positive
RSI
61.22
Neutral
STOCH
14.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNOA, the sentiment is Positive. The current price of 4.45 is above the 20-day moving average (MA) of 4.28, above the 50-day MA of 3.67, and above the 200-day MA of 3.04, indicating a bullish trend. The MACD of 0.35 indicates Positive momentum. The RSI at 61.22 is Neutral, neither overbought nor oversold. The STOCH value of 14.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNOA.

Sonoma Pharmaceuticals Risk Analysis

Sonoma Pharmaceuticals disclosed 35 risk factors in its most recent earnings report. Sonoma Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sonoma Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.33-41.39%2.23%23.26%-2.03%
51
Neutral
$7.31M-78.73%17.43%75.52%
46
Neutral
$8.49M-152.92%70.02%82.33%
44
Neutral
$6.56M-25.65%19.22%98.73%
41
Neutral
$3.09M1155.92%
41
Neutral
$4.53M-52.05%-29.64%73.63%
32
Underperform
$3.53M-551.04%31.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SNOA
Sonoma Pharmaceuticals
4.71
1.51
47.19%
CPHI
China Pharma Holdings
1.42
-0.53
-27.18%
EVOK
Evoke Pharma
5.20
1.21
30.33%
RDHL
RedHill Biopharma
1.30
-7.42
-85.09%
SBFM
Sunshine Biopharma
1.44
-1.45
-50.17%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
3.38
-55.87
-94.30%

Sonoma Pharmaceuticals Corporate Events

Executive/Board ChangesShareholder Meetings
Sonoma Pharmaceuticals Holds Annual Stockholders Meeting
Neutral
Aug 29, 2025

On August 27, 2025, Sonoma Pharmaceuticals held its annual stockholders meeting where several key proposals were voted on. Dr. Jay Birnbaum was elected as a Class II director, executive compensation for the year ended March 31, 2025, was approved, Frazier & Deeter, LLC was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2026, and a proposal to adjourn the meeting for further proxy solicitation was also approved.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 15, 2025